Modality
Small Molecule
MOA
Anti-Tau
Target
Tau
Pathway
Ferroptosis
ETEpilepsyFSGS
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Jul 2030
Phase 1Current
NCT03404929
1,925 pts·ET
2018-05→2030-07·Recruiting
NCT07034260
2,173 pts·Epilepsy
2019-07→2027-08·Not yet recruiting
4,098 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-07-119mo agoPDUFA· FSGS
2026-09-145mo awayFast Track· FSGS
2027-08-021.3y awayPh2 Data· Epilepsy
2030-07-134.3y awayPh2 Data· ET
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Not yet…
Catalysts
PDUFA
2025-07-11 · 9mo ago
FSGS
Fast Track
2026-09-14 · 5mo away
FSGS
Ph2 Data
2027-08-02 · 1.3y away
Epilepsy
Ph2 Data
2030-07-13 · 4.3y away
ET
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03404929 | Phase 1/2 | ET | Recruiting | 1925 | NT-proBNP |
| NCT07034260 | Phase 1/2 | Epilepsy | Not yet recr... | 2173 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET |